CTRI/2022/02/040081已完成3 期
ââ?¬Å?A Multicentric, Randomized, Double Blind, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC of Azilsartan Medoxomil 40 mg plus Amlodipine 5 mg Tablets and FDC of Azilsartan Medoxomil 80 mg plus Amlodipine 5 mg Tablets Versus FDC of Telmisartan 40 mg plus Amlodipine 5 mg Tablets in Patients with Stage 2 Hypertension.ââ?¬?
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 309
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female patients between 18 to 65 years of age (both inclusive).
- •2. Treatment-NaÃ?¯ve patients who are suffering from Stage 2 Hypertension.
- •3. Patients diagnosed with mean sitting SBP of ââ?°Â¥160 to ââ?°Â¤180 mmHg and mean sitting DBP ââ?°Â¥100 to ââ?°Â¤110 mmHg (3 readings will be taken by validated automated blood pressure machine in sitting position, first reading will be taken after 15 min. rest and subsequent two readings will be recorded at the interval of 2 min. each).
- •4. Patients who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
排除标准
- •1. Suspected hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •2. Has clinical laboratory evaluations (including biochemistry and hematology) are not within the reference range for the testing laboratory and the results are deemed clinically significant by the investigator.
- •3. Patients with known case of secondary or malignant hypertension.
- •4. Patients with evidence of postural hypotension (defined as drop in >20 mg of Hg for systolic blood pressure and >10 mm of Hg for diastolic blood pressure after assuming the standing posture from supine or sitting position).
- •5. Patients with known case of symptomatic congestive heart failure, unstable angina pectoris, sinus node dysfunction and any clinically significant cardiac arrhythmias.
- •6. Patient who has had myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery in last 1 year.
- •7. Patients with known case of stroke.
- •8. Patients with abnormal eGFR ( <60 mL/min/1.73 m2).
- •9. Patients with known case of bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one functioning kidney.
- •10. Patients with hyponatremia as per blood biochemistry results at screening.
- •11. Patients with hyperkalemia and hypokalemia as per blood biochemistry results at screening.
- •12. Patients with clinically significant impaired hepatic function [SGOT & SGPT more than 2.5X the UNL and Total bilirubin more than 1.5X the UNL].
- •13. Patients with abnormal thyroid function test (TSH).
- •14. Patients with known case of type 1 diabetes and type 2 diabetes mellitus whose diabetes has not been stable and controlled for the previous three months and with HbA1c value greater than 8%.
- •15. Patients with medical history of any oncological conditions.
- •16. Patients with known case of epileptic seizures.
- •17. Patients with clinical history of bipolar disorder.
- •18. Patients with known case of HIV, hepatitis B & C.
- •19. Pregnant or lactating women.
- •20. Women of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception [which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, some IUDs, sexual abstinence or vasectomised partner, during the study therapy.
- •21. Concurrent participation in another clinical trial or any investigational therapy within 90 days prior to signing informed consent.
- •22. Currently taking prohibited medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •23. Suspected inability or unwillingness to comply with the study procedures.
研究者
相似试验
已完成
3 期
A clinical study to assess the efficacy and safety of Imeglimin Tablets in patients with diabetes.CTRI/2022/02/040348Exemed Pharmaceuticals216
已完成
3 期
A clinical study to investigate the effect of fixed dose combination of Pregabalin plus Mecobalamin plus Nortriptyline Tablets for the treatment of diabetic peripheral neuropathic pain with coexistent Vitamin B12 deficiency in adult patients.CTRI/2020/12/029792Synokem Pharmaceuticals Ltd210
尚未招募
3 期
A Multicentric Randomized Double Blind Double Dummy Parallel Group Comparative Phase III Clinical Study to Evaluate the Efficacy Safety and Tolerability in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).CTRI/2022/11/047055Ajanta Pharma Limited
招募中
3 期
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.CTRI/2024/01/062147Ravenbhel Healthcare Pvt. Ltd.
尚未招募
3 期
A clinical study to assess the efficacy and safety of Pregabalin, Duloxetine and Mecobalamin Capsules in neuropathic pain patients.CTRI/2024/03/063691Synokem Pharmaceuticals Ltd